Alprostadil (Caverject/MUSE) Cost in Michigan 2026

What Does Alprostadil Cost in Michigan Without Insurance?

Cash-pay patients in Michigan face a list price of roughly $600 per month for branded alprostadil products in 2026. That figure applies to both Caverject (Pfizer's intracavernosal injection) and MUSE (the intraurethral suppository). Generic injectable alprostadil is available and typically priced 20 to 40% below the branded Caverject rate at Michigan retail chains, though actual shelf prices vary by pharmacy. GoodRx and similar discount platforms sometimes bring a 6-injection Caverject kit down to $450, $520 at Detroit-area chains, though pricing changes weekly and must be verified at the point of dispensing.

Alprostadil works by binding prostaglandin E1 receptors in cavernosal smooth muscle, triggering cyclic AMP accumulation and relaxing vascular tone to produce erection 1. The mechanism is entirely distinct from PDE5 inhibitors such as sildenafil, which is why alprostadil remains a viable option when oral agents fail 2. Linet and Ogrinc's landmark 1996 NEJM trial (N=296) showed that intracavernosal alprostadil produced successful intercourse in 94% of injection attempts versus 11% with placebo 3. That efficacy profile justifies cost-sharing discussions even at premium list prices.

The FDA first approved the Caverject formulation in 1995 under NDA 019995, with full prescribing information housed at the FDA accessdata portal 4. MUSE (alprostadil urethral suppository) received separate approval in 1996 under NDA 020654 5. Both remain Schedule-exempt prescription drugs, not controlled substances, under federal and Michigan state law 6.

For patients paying out of pocket, the dose-per-use math matters more than the monthly figure. A typical Michigan man using alprostadil two to four times per month at 10 to 20 mcg per injection may obtain 6-injection kits, making the per-encounter cost $75, $100 at cash-pay retail or as low as $10, $25 through compounding pathways described later.

Does Michigan Medicaid Cover Alprostadil?

Michigan Medicaid (Healthy Michigan Plan and traditional Medicaid fee-for-service) covers alprostadil for refractory erectile dysfunction, but a prior authorization (PA) is required before the claim will adjudicate. Without PA, pharmacies will reject the claim at the point of sale. The clinical threshold for PA approval generally requires documentation that the patient has tried and failed at least one oral PDE5 inhibitor, or has a contraindication to PDE5 inhibitor use such as concurrent nitrate therapy.

The Michigan Department of Health and Human Services (MDHHS) publishes its pharmacy benefit criteria through the Medicaid Provider Manual 7. Clinicians submitting PA requests should include the diagnosis code (ICD-10 N52.x for erectile dysfunction), evidence of PDE5 inhibitor failure or contraindication, and the intended alprostadil formulation and dose. Approvals are typically valid for 12 months and renewable. Denials can be appealed; the appeal process is outlined in the MDHHS fair-hearing rules 8.

Managed care plans under Medicaid, including Meridian Health Plan of Michigan and Molina Healthcare of Michigan, maintain their own PA forms but must adhere to MDHHS formulary guidelines. Patients should contact their specific plan's pharmacy helpline to confirm current tier placement and copayment structure. Copayments for Medicaid beneficiaries are nominal, typically $1, $3 per prescription after PA approval.

A 2022 analysis of erectile dysfunction medication access in Medicaid populations found that PA requirements reduce initial fill rates by approximately 30%, though most properly documented requests are ultimately approved 9. Starting the PA process before the patient leaves the clinic visit shortens the delay to first dose.

The HealthRX clinical team uses the following PA preparation checklist for Michigan Medicaid alprostadil requests:

1. Confirm ICD-10 N52.x diagnosis is coded at the visit.
2. Document at least one PDE5 inhibitor trial (drug name, dose, duration, reason for failure) or contraindication.
3. Specify the alprostadil product, dose range, and anticipated injection frequency.
4. Attach relevant comorbidities (diabetes, post-prostatectomy status, vascular disease) that support medical necessity.
5. Submit PA to the correct MCO fax line, not MDHHS directly, if the patient is on a managed care plan.

Is Compounded Alprostadil Legal in Michigan?

Compounded alprostadil is legal in Michigan when prepared by a pharmacy holding a valid 503A license under the federal Drug Quality and Security Act (DQSA) of 2013 10. Section 503A of the DQSA permits state-licensed pharmacies to compound drug products for individual patients upon receipt of a valid prescription, provided the active pharmaceutical ingredient (API) appears on FDA's list of bulk substances available for compounding 11. Alprostadil API meets that criterion.

The Michigan Board of Pharmacy, operating under the Michigan Public Health Code MCL 333.17748, requires compounding pharmacies to maintain USP <797> sterile compounding standards for injectable alprostadil preparations 12. These standards govern beyond-use dating, environmental monitoring, and personnel training. Patients receiving compounded injectable alprostadil should verify that their Michigan pharmacy holds an active sterile compounding endorsement, which can be checked through the Michigan LARA license lookup tool.

Compounded alprostadil injections are typically formulated at 10 to 40 mcg/mL concentrations in bacteriostatic sodium chloride, often in multi-dose vials. Some Michigan compounding pharmacies also prepare trimix (alprostadil combined with papaverine and phentolamine) under the same 503A framework, which offers broader dosing flexibility for men who respond partially to alprostadil monotherapy 13.

503B outsourcing facilities, which compound without patient-specific prescriptions for office use, operate under stricter FDA registration requirements. Only a subset of 503B facilities carry alprostadil, and Michigan urologists stocking office-use vials should confirm the facility's current FDA registration status at the FDA 503B database 14.

The cost advantage of compounded alprostadil is substantial. Michigan 503A pharmacies typically charge $40, $80 for a multi-dose vial providing 10, 20 doses, translating to $2, $8 per injection. Patients with generous insurance or Michigan Medicaid coverage for branded alprostadil may find the brand product cheaper after benefits, so cost comparison at the individual level is warranted before switching to compounding.

How Does Commercial Insurance Cover Alprostadil in Michigan?

Coverage varies sharply by plan design. Most large Michigan commercial insurers, including Blue Cross Blue Shield of Michigan, Priority Health, and HAP, list alprostadil on their formularies but typically at Tier 3 or Tier 4 specialty placement. A Tier 3 copayment for a non-preferred brand runs $60, $120 per fill at standard Michigan plans in 2026; Tier 4 coinsurance can reach 25 to 50% of the negotiated price, which on a $600 list product means $150, $300 per fill even with insurance.

The ACA benchmark plans sold on the Michigan Marketplace (HealthCare.gov) are not required to cover erectile dysfunction medications, and many Silver and Bronze plans specifically exclude them 15. Employer-sponsored plans have more flexibility and sometimes include alprostadil under a medical benefit rather than pharmacy benefit, particularly when the injection is administered in a urology office setting and billed under CPT 99213 plus J0270 (injection, alprostadil, 1.25 mcg).

Pfizer's patient assistance program, RxPathways, covers Caverject for uninsured or underinsured Michigan patients meeting income thresholds (generally at or below 400% of the federal poverty level) 16. Applications require a signed prescriber statement and proof of income. Processing takes two to four weeks. The program ships product directly to the prescriber's office in most cases.

Step therapy requirements are common. Several Michigan BlueCross plans require a 90-day trial of a PDE5 inhibitor before approving alprostadil, even for patients with documented PDE5 failure. Prescribers can request a step therapy exception using Michigan's standard prior authorization exception form, citing documented contraindication or clinical failure 17.

Can Michigan Patients Get Alprostadil Through Telehealth?

Telehealth prescribing of alprostadil is fully permitted in Michigan as of 2026. Michigan's telehealth parity law (PA 129 of 2020) requires commercial insurers to cover telehealth services on the same basis as in-person visits 18. A physician or advanced practice provider licensed in Michigan may conduct a synchronous audio-video evaluation, establish a diagnosis of erectile dysfunction, and send an alprostadil prescription to a Michigan-licensed pharmacy, including a 503A compounding pharmacy, without an in-person visit.

The prescriber must still complete a thorough assessment. This includes reviewing cardiovascular history, current medications (nitrate interactions are an absolute contraindication to any vasodilatory ED therapy) 19, and discussing proper injection technique. Self-injection training traditionally requires an in-person demonstration in a urology or men's health clinic, but video-guided training with instructional materials has become accepted practice at several Michigan telehealth platforms. The FDA labeling for Caverject specifies that patients should be trained before self-injection and the lowest effective dose identified 20.

Michigan Medicaid also covers synchronous telehealth visits for established Medicaid beneficiaries under the 2020 telehealth expansion rules 21. A Medicaid telehealth visit that results in an alprostadil PA request is treated the same as an in-person PA initiation. The PA paperwork, however, still requires submission through standard MDHHS channels.

HealthRX clinicians conduct Michigan telehealth evaluations for erectile dysfunction under these protocols. After history review and clinical assessment, prescriptions can be routed to the patient's preferred Michigan retail pharmacy or to a partner 503A compounding pharmacy depending on the patient's insurance situation and cost preferences.

What Is the Cheapest Way to Get Alprostadil in Michigan?

The lowest realistic out-of-pocket path for most Michigan men in 2026 runs through a licensed 503A compounding pharmacy. At $40, $80 per multi-dose vial covering 10, 20 injections, the per-use cost is $2, $8, compared to $75, $100 per injection at retail cash pay for branded Caverject. Patients who use alprostadil infrequently (one to three times per month) may find that a single compounded vial lasts the entire month for under $50 total.

For patients who prefer or require the branded product, combining a manufacturer savings card with a pharmacy discount program produces the next-lowest cost. Pfizer's Caverject Impulse savings card, when available, reduces copayments for commercially insured patients to as low as $0 for the first fill and $30, $50 for subsequent fills at participating Michigan pharmacies 22. These cards cannot be used by Medicare or Medicaid beneficiaries under federal anti-kickback rules.

GoodRx coupons at Michigan pharmacies including CVS, Walgreens, Meijer, and Rite Aid typically discount generic alprostadil injection kits to $420, $530 depending on the dose strength and kit size. MUSE (urethral suppository) coupons run slightly higher at $500, $560 because no generic suppository form is widely available in Michigan at this time.

The cost decision tree looks like this for most Michigan patients: First, check whether commercial insurance or Michigan Medicaid will cover the product after PA, because covered cost is typically $1, $120 per fill. If coverage is denied or cost-sharing exceeds $150 per month, a licensed 503A compounding pharmacy is the most cost-effective path. If branded product is clinically preferred and insurance denies coverage, apply for Pfizer's RxPathways assistance program before paying retail.

Alprostadil Dosing and Safety: What Michigan Prescribers Should Know

Caverject intracavernosal injection is started at 1.25 to 2.5 mcg in men with neurogenic erectile dysfunction (for example, post-radical prostatectomy patients) and 2.5 to 5 mcg in men with vasculogenic or psychogenic etiology 23. The dose is titrated in the clinic or via telehealth follow-up in 5-mcg increments until the patient achieves an erection lasting 30 to 60 minutes. The maximum single dose is 60 mcg. Injections should not exceed one per 24-hour period and no more than three per week per FDA labeling.

MUSE suppositories are inserted 5 to 10 minutes before intercourse. The starting dose is 125 to 250 mcg; the effective dose range is 125, 1 to 000 mcg. MUSE produces erections in approximately 43% of men in clinical settings, lower than the intracavernosal route, but the urethral route is preferred by patients who cannot manage self-injection 24.

Priapism (erection lasting more than 4 hours) is the primary safety concern. Patients must receive written instructions to proceed immediately to an emergency department if erection persists beyond 4 hours. The reported rate of prolonged erection requiring intervention in the Linet 1996 NEJM trial was 1.5% 25. Michigan emergency departments treat priapism with intracavernosal phenylephrine per the American Urological Association (AUA) 2021 guidelines on priapism management 26.

Pain at the injection site occurred in approximately 10.5% of patients in the 1996 NEJM trial 27. Switching to a lower concentration compounded formulation or using a finer-gauge needle (27, 30G) often reduces injection-site discomfort.

Cardiovascular screening before initiating alprostadil follows the Princeton Consensus guidelines, which stratify patients into low, intermediate, and high cardiac risk before any ED therapy is started 28. Low-risk patients (stable coronary disease, controlled hypertension, asymptomatic with fewer than three major cardiovascular risk factors) may begin alprostadil without further cardiovascular workup. Intermediate and high-risk patients require cardiology evaluation first.

Alprostadil vs. PDE5 Inhibitors: When Does Michigan Make the Switch?

Sildenafil, tadalafil, and vardenafil are first-line oral agents for ED because of their convenience and lower cost at generic pricing. Generic sildenafil runs $10, $30 per month in Michigan in 2026, making it roughly 20 times cheaper than brand alprostadil at list price. However, PDE5 inhibitors require intact nitric oxide signaling in the cavernous nerves, and this pathway is disrupted in several common Michigan patient populations 29.

Post-prostatectomy patients with bilateral nerve resection respond to PDE5 inhibitors at rates as low as 20 to 30%. A 2004 analysis (N=91 post-radical prostatectomy men) found that intracavernosal alprostadil produced satisfactory erections in 72% of patients who had failed sildenafil 100 mg 30. Diabetic men with autonomic neuropathy, men on alpha-blocker therapy for benign prostatic hyperplasia, and men with severe arterial insufficiency similarly show higher response rates with injectable alprostadil than with oral PDE5 inhibitors.

"Alprostadil remains the most pharmacologically reliable option for men with cavernous nerve damage, offering direct smooth-muscle relaxation independent of neural input," according to the AUA's erectile dysfunction guideline panel statement on second-line therapies 31. The 2018 AUA guideline (updated 2021) classifies intracavernosal vasoactive agents, including alprostadil, as second-line therapy after failure of or contraindication to oral PDE5 inhibitors 32.

Men who have tried at least two different PDE5 inhibitors at maximum tolerated doses on at least four separate occasions, without adequate response, meet the AUA threshold for second-line therapy. This documentation also satisfies most Michigan insurance PA criteria for alprostadil.

Michigan-Specific Resources for Alprostadil Patients

Michigan residents have several state-specific access pathways that out-of-state guides often omit. The Michigan Department of Insurance and Financial Services (DIFS) operates a consumer helpline (1-877-999-6442) that assists residents in resolving insurance coverage disputes, including step-therapy overrides and PA denials for alprostadil 33. DIFS processed over 4,200 pharmacy-related insurance complaints in 2023, and ED medication coverage denials are among the categories reviewed.

The Michigan Prescription Drug Affordability Commission, established in 2023, monitors prescription drug pricing and may create cost-sharing assistance programs for high-cost medications. Alprostadil has been discussed in MPDAC public hearings as a candidate for pricing review given its $600 list price relative to the cost of the active pharmaceutical ingredient 34.

The University of Michigan Urology and Henry Ford Health urology programs in Detroit operate self-injection training clinics that pair with telehealth follow-up, allowing Michigan patients to receive their initial in-person injection under clinical supervision before transitioning to home self-injection with telehealth monitoring 35. This hybrid model satisfies both FDA labeling requirements for supervised initial dosing and Michigan telehealth parity requirements for follow-up coverage.

Patients below 200% of the federal poverty level who are not Medicaid-eligible may qualify for the Michigan Primary Care Association's 340B drug pricing program at Federally Qualified Health Centers (FQHCs) across the state 36. Under 340B pricing, alprostadil acquisition costs to the FQHC may be 30 to 50% below wholesale acquisition cost, and savings are often passed through to uninsured patients as reduced prescription prices.

The Michigan Cancer Consortium notes that post-prostatectomy erectile dysfunction is one of the most common survivorship concerns among the estimated 8,900 new prostate cancer cases diagnosed in Michigan annually 37. Several Michigan hospital systems have established dedicated prostate cancer survivorship clinics where alprostadil prescribing, insurance navigation, and self-injection training are bundled into a single visit.

Men whose erectile dysfunction results from prostate cancer treatment may also qualify for Medicare Part D coverage of alprostadil if the prescriber documents the oncologic etiology, even though Medicare generally excludes drugs "used for treatment of sexual or erectile dysfunction" under the Part D exclusion statute. Oncologic post-surgical indication documentation can sometimes overcome this exclusion at the plan level; a Medicare coverage determination request is the correct mechanism 38.

In Michigan, a patient who takes the following steps in order will typically achieve the lowest possible cost: confirm diagnosis with a licensed Michigan prescriber via telehealth or in-person visit, submit Michigan Medicaid or commercial insurance PA with full documentation, obtain the manufacturer savings card if commercially insured, and, if coverage is denied, proceed to a licensed 503A compounding pharmacy with a valid prescription. At a licensed Michigan 503A pharmacy, a 30-dose compounded alprostadil vial at 20 mcg/mL commonly costs $50, $80 total, placing per-injection cost at $1.67, $2.67.